MedicGo
Effects of dexmedetomidine on stress hormones in patients undergoing cardiac valve replacement: a randomized controlled trial.
Metadata
Journalbmc anesthesiology1.695Date
2020 Jun 06
5 months ago
Type
Journal Article
Volume
2020-Jun-06 / 20 : 142
Author
Wu H 1, Tang J 2, Pan J 1, Han M 1, Cai H 1, Zhang H 3
Affiliation
  • 2. Department of Anesthesiology, Third Affiliated Hospital of Zunyi Medical University, Zunyi, 563003, Guizhou Province, China.
  • 3. Department of Anesthesiology, Affiliated Hospital of Zunyi Medical University, No. 149 Dalian Road, Huichuan District, Zunyi, 563003, Guizhou Province, China. [email protected]
Doi
PMIDMESH
Abstract
BACKGROUND: Stress response always occurs in cardiac valve replacement patients undergoing cardiopulmonary bypass (CPB).
METHODS: 60 patients undergoing cardiac valve replacement were recruited and randomized into control and Dex groups. Dex group received 1.0 μg·kg-1 of Dex for 10 min intravenously before anesthesia, followed by 0.5 μg·kg-1·h-1 of Dex, steadily administered throughout the procedure. And controlled group received the identical velocity of saline as Dex group. Plasma level of cortisol (Cor), epinephrine (E), norepinephrine (NE), and serotonin (5-HT) were evaluated at four timepoints: Before administration (T0), sawn sternum (T1), end of extracorporeal circulation (T2), and 24 h post operation (T3). General data of operation and recovery such as heart rate (HR), mean arterial pressure (MAP), intraoperative bispectral index (BIS), and hospitalization time in the intensive care unit (ICU) were also compared.
RESULTS: Increase of Cor, E, NE, and 5-HT for the Dex group was significant lesser than that in the control group (P < 0.05), and ICU hospitalization time and ventilator support time was significantly shorter in the Dex group. The proportion of patients discharged from the hospital with better prognosis was significantly higher than that in the control group, while there were no significant differences in hospitalization costs and vasoactive drugs use between the two groups.
CONCLUSIONS: Dex reduces plasma Cor, E and NE elevations in patients after CPB, alleviates the stress reaction of the body, shortens the hospitalization time and ventilator support time in ICU, and plays a positive role in the rehabilitation of patients undergoing cardiac valve replacement.
TRIAL REGISTRATION: China Clinical Trial Registry (No. ChiCTR-IPR-17010954) March 22rd, 2017.
Keywords: Cardiopulmonary bypass Dexmedetomidine Hormones
Fav
Like
Download
Share
Export
Cite
1.7
BMC Anesthesiolbmc anesthesiology
Metadata
LocationEngland
FromBMC

No Data

© 2017 - 2020 Medicgo
Powered by some medical students